Drugs / Tritanrix-HepB/Hib-MenAC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00136604 | Jan → Apr 2006 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tritanrix-HepB/Hib-MenAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00136604 ↗ |
| Modality | Vaccine | “Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine” NCT00136604 ↗ |
| Route | Intramuscular | “intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm” NCT00136604 ↗ |